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Results:
There were twenty-one patients in the historic control group.
The total cost of the hospital admissions was $AUD1,771,448
(average $AUD84,354, range $AUD28,856-276,989). Total phar-
maceutical costs for all 21 patients was $AUD 798,583, represent-
ing 45% of total costs.
Twenty (95%) patients in the historical group experienced mu-
cositis with 48% having grade 3 or 4. All ﬁve patients who received
palifermin experienced mucositis but no patients had grade 3 or 4.
The average number of TPN days was 8.3 days (median 9.5 days)
in the control group compared to 12.2 days (median 9.0 days) in
palifermin recipients. Patients that received palifermin had a mean
LOS of 34.4 days (median 25 days) compared to mean of 36.5 days
(median 35) for the control group.
Conclusion:
Palifermin usage was associated with a decreased incidence and
severity of oral mucositis with a reduction in LOS, antibiotic and
antifungal costs. Further validation of these results is required in a
larger cohort of patients.
Impact of Degree of Mucositis and Usage of Palifermin
Historical
Contol
(n21)
Palifermin
treated
group
(n5)
Mucositis any Grade - mean
days duraton
14 8
Mucositis Grade 3 or 4 -
mean days duration
3.3 0
Mucositis grade 3 or 4 - pts
(%)
11 (52.4) 0 (0)
TPN usage - mean days
duration
8 12.2
TPN usage - median days
duration
9.5 9.0
Duration of hospitalisation -
mean days
36.5 34.4
Duration of hospitalisation -
median days
35.0 25.0
Antifungal usage - mean
$AUD
$15,728 $12,854
Antifungal usage - median
$AUD
$10,720 $2,389
Total cost antibiotics,
antifungals, TPN - mean
$AUD
$20,929 $18,811
Total cost antibiotics,
antifungals, TPN -
median $AUD
$15,553 $5,605
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IMPACT OF PALIFERMIN ON HOSPITAL RESOURCE CONSUMPTION
ASSOCIATED WITH ALLOGENIC PERIPHERAL BLOOD TRANSPLANTA-
TION AND TOTAL BODY IRRADIATION
Dooley, M.J.1, Schwarer, A.1, Radhakrishnan, M.1, Poole, S.G.1,
Neville, M.A.2, Jennifer, L.2, Farag, S.1 1The Alfred, Melbourne,
Victoria, Australia; 2Pretium Pty Ltd, Sydney, New South Wales,
Australia.
Background: The impact of oral mucositis associated with au-
tologous stem cell transplantation (SCT) following high dose che-
motherapy and radiotherapy has been evaluated in the clinical trial
setting to assess the effects of palifermin. The impact of palifermin
in the allogenic peripheral blood (PBSCT) and TBI and the costs
associated has not been quantiﬁed.
Aim:
To perform an analysis of the costs associated with allogenic
PBSCT in patients who received TBI and assess the impact of oral
mucositis and palifermin.
Method:
The costs associated with patients undergoing allogenic PBSCT
and TBI following high dose chemotherapy were quantiﬁed. Consec-
utive patients who received palifermin (Oct 05-July 06) and a control
group (June 04-Oct 05) that had not were included. Costs were
determined through data extracts from the hospital’s clinical costing
system and through retrospective medical record review. Incidence,
duration and grade of mucositis, length of hospital stay (LOS), anti-
infective use and requirements for total parenteral nutrition (TPN)
were quantiﬁed.
Results:
There were eleven patients in the historic control group and ten
(91%) experienced mucositis. Five patients were evaluated in the
palifermin group and all experience mucositis. The average number of
days of oral mucositis was 8.0 days in the palifermin group compared
to 17 days in the control group. None of the palifermin treated
patients experienced grade 3 or 4 mucositis compared to 73% in the
control group who had an average duration of Grade 3-4 mucositis of
8 days (median 6 days). Patients that received palifermin had a mean
LOS of 34.4 days (median 25.0 days) compared to mean of 36.5 days
(median 28) for the control group. The average number of TPN days
with palifermin recipients was 12.2 days (median 9.0 days) compared
to 8 days (median 9 days) in the control group. For one patient who
received palifermin, TPN usage (37 days) was indicated for severe
nausea rather thanmucositis. The total costs of antibiotics, antifungals
and TPN during the period of hospitalisation was on average
$AUD18,811 (median $AUD5,606) for those patients who received
palifermin compared to $AUD18,324 (median $AUD$8,856) for
those that did not .
Conclusion:
Palifermin usage was associated with a substantial decreased
incidence and severity of oral mucositis with a reduction in LOS in
patients who received TBI with allogenic PBSCT. Further valida-
tion of these results is required in a larger cohort of patients.
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ROLE OF TRANSFUSION IN STEM CELL TRANSPLANTATION: A FREE-
DOM-FROM-TRANSFUSION (FFT), COST AND SURVIVAL ANALYSIS
Ganguly, S.1, Bradley, J.P.1, Skikne, B.S.1, Divine, C.L.1,
Deauna-Limayo, D.1, Bodensteiner, D.B.1, Patel, J.S.1 1University of
Kansas Medical Center, Kansas City, KS.
Introduction: Transfusion of blood products is often an integral
part of stem cell transplantation (SCT). Little literature exists to
deﬁne the impact of transfusion on the outcome of SCT.
Methods: In an attempt to evaluate the need and volume of
transfusion in patients undergoing SCT in our institution, we
retrospectively evaluated the records of all patients who received
SCT from 1995 till 2000.
Results:Out of 210 patients, 154 patients received autologous SCT
and 56 patients received allogeneic SCT between 1995 and 2000.
Non-Hodgkin’s lymphoma (53%) and leukemia (73%) were the most
frequent indications for autologous and allogeneic SCT respectively.
Peripheral blood stem cell (PBSC) was used in all but one patient
undergoing autologous SCT. Fifty patients received PBSC and 16
patients received bone marrow as the source of stem cells during
allogeneic SCT. One hundred thirty eight (90%) out of 154 patients
undergoing autologous SCT and 24 (43%) out of 56 patients with
allogeneic SCT exhibited total hematopoietic engraftment and free-
dom from transfusion (FFT). Time to achieve FFT in days (median;
range) for RBC units for autologous SCT (12; 0-183) was signiﬁcantly
shorter compared with allogeneic SCT (16.5; 0-373). Number of
RBC units (median; range) transfused were less in patients undergoing
autologous SCT (4; 0-26) compared with patients undergoing allo-
geneic SCT (6.5; 0-54). The median cost of transfusion was signiﬁ-
cantly higher in patients undergoing allogeneic transplantation (Red
cell: $2015; and Platelet: $4480) compared to patients undergoing
autologous transplantation (Red cell: $1240 and Platelet: $2520). The
number of transfused RBC and platelet units negatively correlated
with overall survival (median duration of follow-up: 1.3 years) in
patients with autologous SCT, but not in patients with allogeneic
SCT. This signiﬁcance remained valid in both continuous regression
analysis by Cox and dichotomous analysis (above and below median
number of transfused units) by Kaplan-Meier.
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Conclusions: We conclude that transfusion of blood products is
an integral part of stem cell transplantation. Role of growth factors
and lowering the threshold of transfusion in an attempt to decrease
the need of transfusion should be studied in a prospective fashion.
Decreased survival in patients receiving more transfusion could be
due to the nature and severity of underlying disease rather than an
independent risk factor for survival.
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VACCINATION AGAINST INFECTION AFTER HAEMOPOIETIC STEM CELL
TRANSPLANT: A SURVEY OF PRACTICE IN THE UK & IRELAND (BRITISH
SOCIETY OF BONE MARROW TRANSPLANTATION)
Gilleece, M.H.1, Towlson, K.2, Wilson, M.2, Littlewood, T.3, Cook, G.1,
Marks, D.I.4 1Leeds Teaching Hospitals Trust, Leeds, Yorkshire, United
Kingdom; 2BSBMT Data Registry, London, United Kingdom; 3Oxford
Radcliffe Hospital, Oxford, United Kingdom; 4Bristol Royal Hospital for
Children, Bristol, United Kingdom.
International guidelines recommend revaccination of haemopoietic
stem cell transplant (HSCT) recipients. We surveyed practice in
HSCT centres in the UK & Ireland. The response rate was 29/52
(56%): 9 did autologous (AUTO) transplants only & 20 performed
allografts/autografts in adults &/or children (AUTO/ALLO). Re-
sponders represented 58% of recorded transplants (2003-2005).
Vaccination post-autologous HSCT was intended by 4/9 AUTO
centres and 12/20 AUTO/ALLO centres. Vaccinations post-au-
tograft were given by centres as follows: Combined/selective Diph-
theria, Tetanus & Pertussis (DTP) (38%), Haemophilus B (HiB)
(45%) , Meningococcus C (MC) (34%), Poliomyelitis (Polio) (31%,
Salk), Hepatitis A (HA) (3%), Inﬂuenza A (Flu A) (45%) and Strep-
tococcus pneumoniae (SP) (45%). Selected patients were routinely
vaccinated against Measles / Mumps / Rubella (MMR) (28% centres)
and Hepatitis B (HB) (10%). Antibody titres or CD4 cell counts
guided timing of post-autologous HSCT vaccination in 4 & 1 centre
respectively.
Vaccinations post-allograft were planned by centres as follows:
DTP (100%), HiB (90%), MC (80%), Polio (95%, Salk), Flu A
(100%) and SP (95%). Selected patients were routinely vaccinated
against HB (25%) and HA (10%). CD4 cell counts guided timing of
post-allograft vaccination in 2 centres.
Live vaccines were avoided by 4 ALLO/AUTO centres: MMR was
given at 18-30 months post allograft in the rest provided there was no
active Graft versus Host Disease or ongoing Immunosuppressive
medication (I/S) . Bacillus Calmette Guerin was considered by 1
centre for high risk patients without GVHD or I/S.
Household contacts were advised to consider vaccination against Flu
A in 17% centres while Salk polio vaccine was advised by 10% centres.
Penicillin V prophylaxis against SP was recommended by 6
centres post Autograft for 6-12 months or life if Total Body
Irradiation had been given. Lifelong penicillin was advocated for
all allografted patients by 9 centres and in selected patients by 3
centres. Episodes of severe Pneumococccal sepsis was reported by
24% centres independent of prior vaccination or penicillin.
Reasons for large variation, particularly among autologous HSCT
recipients, may include lack of Grade A evidence, perceived poor
efﬁcacy and patient non-compliance. Systematic multicentre prospec-
tive evaluation of immune-reconstitution and incidence of speciﬁc
infections may clarify the value of post SCT vaccination in prevention
of life threatening infection.
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PROPHYLACTIC RED BLOOD CELL EXCHANGE FOR PREVENTION OF SE-
VERE HEMOLYSIS AFTER MINOR ABO-INCOMPATIBLE STEM CELL TRANS-
PLANTATION FOLLOWING REDUCED-INTENSITY CONDITIONING
Worel, N.1, Mitterbauer, M.2, Leitner, G.1, Rabitsch, W.2,
Greinix, H.2, Kalhs, P.2, Hoecker, P.1 1Dpt. f. Transfusion Medicine,
University Hospital, Vienna, Austria; 2Dpt. f. Bone Marrow Transplan-
tation, University Hospital, Vienna, Austria.
Background: In about 20% of allogeneic stem cell transplantation
(SCT) minor ABO incompatibility does exist. This is accompanied
with the risk of severe hemolysis especially during hematopoietic
regeneration. The risk of hemolysis increases if peripheral blood stem
cells are used instead of bone marrow (BM) and a graft-versus-host
disease (GvHD) prophylaxis without methotrexate (MTX). As we
have observed lethal hemolyses in patients undergoing minor ABO
mismatched SCT following reduced intensity conditioning (RIC) we
decided to perform prophylactic red blood cell exchange (RBCX) in
all consecutive patients undergoing RIC prior to SCT with a minor
ABO incompatible donor.
Materials and Methods: From April 1999 to March 2006, 112
consecutive patients underwent SCT with a sibling (n55) or unre-
lated donor graft (n57) after RIC. GvHD prophylaxis consisted of
CyA and mycophenolate mofetil (MMF). Fifty-four patients had an
ABO-identical donor, 33 received an ABO-minor/bidirectional and
25 an ABO-major incompatible graft, respectively. RBCX was per-
formed between day -5 and -1, removing 1 time patients RBCmass to
reduce his remaining RBCs to about 40%. Packed RBCS of group 0
were used as exchange ﬂuid.
Results: So far, 20 patients underwent prophylactic RBCX before
SCT. The procedure was tolerated well in 16 (80%) patients, 2
developed citrate toxicity and 2 nausea and hypotension during treat-
ment leading to discontinuation of RBCX in the latter patients.
Whereas 18 patients did not experience any signs of hemolysis after
minor ABO incompatible SCT, 2 showed a marked increase in lactic
dehydrogenase and serum bilirubin levels without a drop of hemato-
crit levels below 28% during hematologic recovery. Six of 20 patients
with prophylactic RBCX died between 4.3 and 29.2 months after
SCT of GvHD and infection (n3), invasive aspergillosis (n1) and
relapse of hematologic disease (n2). One patient rejected his graft
within 1 month. The other 13 (64%) patients are in continuous
complete remission a median of 13.9 months (1.2 to 36) after SCT.
Conclusion: RBCX is a save and well tolerated procedure to pre-
vent severe hemolysis by elimination of the majority of incompatible
recipient RBCs as demonstrated by our data. Whether a more inten-
sive immunosuppression can overcome the risk of hemolysis without
affecting the establishment of donor chimerism remains unclear. Nev-
ertheless, close monitoring of patients at risk between days 5 and 15
after SCT is recommended.
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AN EVALUATION OF INFECTIONS AND RESISTANCE PATTERNS AFTER
IMPLEMENTATION OF ANTIBIOTIC PROPHYLAXIS IN NEUTROPENIC
CANCER PATIENTS
Kennedy, L.D.1, Gatesman, M.L.2, High, K.3, Karchmer, T.B.3 1Wake
Forest University Baptist Medical Center, Winston Salem, NC; 2Uni-
versity of Virginia Medical Center, Charlottesville, VA; 3Wake Forest
University School of Medicine, Winston Salem, NC.
Two recently published trials and a meta-analysis reported signiﬁ-
cantly reduced febrile episodes and mortality, respectively, with the
use of FQ prophylaxis in neutropenic cancer patients. Although this
data supports the use of antibiotic prophylaxis (AP), AP does not come
without risks. A concern exists for breakthrough infections withmulti-
drug resistant (MDR) organisms and colonization with resistant bac-
teria. Our institution initiated the use of AP to prevent febrile neu-
tropenia (FN) in high risk cancer patients after the reports above, and
assessed the efﬁcacy of AP in our patients and the incidence of MDR
infection and colonization in neutropenic cancer patients prior to and
after the implementation of AP.
Patients at high risk for FN (hematopoietic stem cell transplant,
leukemia patients undergoing induction or consolidation chemother-
apy, patients with a history of previous FN or undergoing a chemo-
therapy regimen with an expected duration of neutropenia 10 days)
were given AP (moxiﬂoxacin 400 mg daily) initiated the day after
chemotherapy and continued until neutropenia resolved or break-
through fever requiring broad spectrum antibiotics occurred.
Preliminary analysis of 81 patients showed that 38 patients (47%)
developed FN with a mean time to febrile episode of 10.9 days.
Eighteen patients were readmitted for FN, in 19 patients FN oc-
curred during the same hospitalization, and one patient was treated as
an outpatient with IV antibiotics. Seventeen (21%) patients had pos-
itive cultures: blood (6), urine (9), sputum (2). The rate of overall
microbiologically documented infection (21%) is similar, but the rate
of bacteremia (7%) lower than those reported in a similar risk patient
group using levoﬂoxacin AP (18%) (NEJM, 2005;335:977). Evalua-
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